Mn Services Vermogensbeheer B.V. Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Mn Services Vermogensbeheer B.V. boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 1.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 93,660 shares of the medical equipment provider’s stock after purchasing an additional 1,700 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Hologic were worth $6,752,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of HOLX. General Partner Inc. purchased a new stake in Hologic in the fourth quarter worth approximately $26,000. Groupama Asset Managment boosted its stake in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC boosted its stake in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares during the period. First Horizon Advisors Inc. boosted its stake in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the period. Finally, Covestor Ltd boosted its stake in shares of Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 133 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.88% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Mizuho dropped their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Morgan Stanley dropped their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Wolfe Research started coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Ten analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Price Performance

HOLX opened at $63.38 on Friday. The stock has a fifty day simple moving average of $69.16 and a two-hundred day simple moving average of $75.94. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $14.22 billion, a price-to-earnings ratio of 19.99, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12-month low of $62.69 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.